

Please type a plus sign (+) inside this box



RECEIVED

FEB 06 2002

1625

TECH CENTER 1600/2900

PTO/SB/21 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM <i>(to be used for all correspondence after initial filing)</i>	Application Number	09/855,710	
	Filing Date	May 16, 2002	
	First Named Inventor	BENNEKER et al.	
	Group Art Unit	1625	
	Examiner Name	CHANG, C.	
Total Number of Pages in This Submission	5	Attorney Docket Number	POT-010US3

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Reply	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	Response to Notice to File Corrected Application Papers and Substitute Specification (31 pages)
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application	Remarks	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Mark R. Buscher Reg. No. 35,006
Signature	
Date	2/1/02

CERTIFICATE OF MAILING	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date: <input type="text"/>	
Typed or printed name	
Signature	Date

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



RECEIVED

FEB 06 2002

TECH CENTER 1600/2900

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:
BENNEKER, et al.

Application No.: 09/855,710

Filed: May 16, 2001

For: 4-Phenylpiperidine Compounds

Atty. Docket: POT-010US3

Examiner: Chang, C.

Group Art Unit: 1625

**Information Disclosure Statement
Pursuant To 37 C.F.R. § 1.97(b)**

Assistant Commissioner for Patents
Washington, D.C. 20231

February 1, 2002


Sir:

Applicants hereby direct the attention of the Patent and Trademark Office to the documents listed on the attached Form PTO-1449. Applicants respectfully request that these documents be expressly considered during the prosecution of this application, be made of record therein, and appear among the "References Cited" on any patent to issue therefrom. A copy of each listed document was previously submitted to or cited by the U.S. Patent and Trademark Office in connection with the parent application U.S. Serial Nos. 08/872,023 and 09/200,743. Accordingly, a copy is not required to be submitted herewith. 37 C.F.R. 1.98(d). However, should the Examiner desire to have a copy of one or more of the enclosed listed documents, she is encouraged to contact applicants' undersigned representative and the desired copies will promptly be forwarded to her.

As the Examiner is aware, the submission of this statement is not to be construed as an admission that any document is prior art to the present invention or that any document is material to patentability as defined in rule 56.

This Information Disclosure Statement is being filed pursuant to 37 C.F.R. § 1.97(b), before the first Office Action on the merits. Therefore, no fee is due.

Respectfully submitted,

A handwritten signature in dark ink, appearing to read "Mark R. Buscher", is written over a horizontal line.

Mark R. Buscher
(Reg. No. 35,006)

Synthon Pharmaceuticals, Ltd
Patent Department
P.O. Box 161
Catharpin VA 20143
703 753 8791